VivoPower PLC
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Tser Fah Chin
- Full Time Employees
- 41
- Sector
- Utilities
- Industry
- Electric utilities
- Address
- Blackwell House London GL United Kingdom EC2V 5AE
- IPO Date
- Dec 29, 2016
- CIK
- 0001681348
- Website
- vivopower.com
- Similar Companies
- Business
- Meridian Bioscience, Inc. is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. The company's core offerings include diagnostic test kits, purified reagents, antibodies, antigens, specialty biologicals, and molecular and immunological reagents used in diagnostic applications. Meridian specializes in products for gastrointestinal and upper respiratory infections, blood lead level testing, parasitology, serology, and fungal disease diagnosis. It also supplies rare reagents and components for life science research, pharmaceutical, and biotech companies across more than 70 countries. Founded in 1976 and headquartered in Cincinnati, Ohio, Meridian serves a diverse customer base including hospitals, reference laboratories, research centers, physician offices, veterinary testing facilities, diagnostics manufacturers, and agri-bio companies. The company’s products are designed to deliver speed, accuracy, and simplicity in diagnostics, often requiring minimal equipment for use outside the human body. In recent developments, Meridian was acquired in a $1.53 billion all-cash transaction by a consortium led by SD Biosensor and SJL Partners, completed in early 2025. This strategic partnership leverages SD Biosensor’s R&D and mass production capabilities alongside Meridian’s U.S. market expertise to accelerate growth in the in vitro diagnostics (IVD) sector. Additionally, Meridian has appointed a new executive leadership team to drive global growth and innovation. The company also recently launched new animal-free immunoassay interference blockers, setting sustainability standards in diagnostic assay development. Meridian continues to expand its life science business through organic growth and acquisitions, including the integration of the Bioline group, which enhances its portfolio with nucleotides, PCR enzymes, and key global operations in the U.K., Germany, and Australia. Meridian Bioscience operates primarily in the medical equipment manufacturing industry, maintaining strong market positions in infectious disease diagnostics and life science research reagents, with a focus on global distribution and strategic innovation in diagnostics and life science materials. All information is current as of late 2025.
Company News
VivoPower shares jump on sovereign AI data center pact
VivoPower, Open Innovation AI to develop sovereign AI data centers across Europe, Gulf and Asia
VivoPower Signs Definitive Heads of Agreement with Open Innovation AI to Develop Secure Sovereign AI Data Centers Across the Nordics, Mainland Europe, the GCC and selective countries in Asia
VivoPower breaks ground on 40MW AI data center conversion in Norway with local contractors
Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany
VivoPower's debt retirement and Nordic restructuring reinforce Outperform case from Noble
VivoPower's debt retirement and Nordic restructuring reinforce Outperform case from Noble
VivoPower to spin off non-Nordic AI data center assets into new Singapore-based platform
VivoPower Approves Independent Listing of 2.2GW Non-Nordic AI Infrastructure Platform, Transferring Capital Expenditure Requirements Whilst Retaining De Facto Control
VivoPower PLC Ordinary Shares (NASDAQ:VIVO) Trading Up 2.8% – Should You Buy?
VivoPower clears $28.8m founder loan ahead of Nordic data centre push
VivoPower Fully Retires US$28.8 Million Shareholder Debt Principal, Strengthening Balance Sheet Ahead of Nordic AI Infrastructure Buildout
VivoPower Fully Retires US$28.8 Million Shareholder Debt Principal, Strengthening Balance Sheet Ahead of Nordic AI Infrastructure Buildout
FTSE 100 Live: London index hits new intraday high, but US in selling mode pre-Fed
Meta profit misses estimates on higher costs
FTSE 100 Live: Blue-chips hit high, but Wall Street in selling mode
VivoPower secures $50M PIPE led by Blue Sky Capital to fund AI data center project
VivoPower Secures US$50 Million PIPE At US$7.50 Conversion Price Per Share
VivoPower announces appointment of Group Finance Director
VivoPower Appoints Group Finance Director